← Search & browse all drugs

danaparoid

B01AB09

Forms & Strengths

Injection: 750 anti-Xa units per 0.6 mL in ampoules

Adult Dosing

Prophylaxis of DVT: 750 anti-Xa units subcutaneously twice daily
Treatment of DVT/PE: Weight-adjusted intravenous bolus followed by continuous infusion (e.g., 1250 to 2500 units IV, then maintenance infusion based on anti-Xa levels)
Hemodialysis anticoagulation: Initial bolus followed by maintenance doses based on dialysis duration and anti-Xa monitoring

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established

Indications

Prophylaxis of deep vein thrombosis (DVT) in patients undergoing elective hip replacement surgery
Treatment of acute DVT and pulmonary embolism
Anticoagulation in patients with heparin-induced thrombocytopenia (HIT) requiring alternative antithrombotic therapy

Mechanism of Action

Glycosaminoglycan mixture (heparan sulfate, dermatan sulfate, chondroitin sulfate) that inhibits factor Xa predominantly via antithrombin III, and thrombin to a lesser extent

Contraindications

Known hypersensitivity to danaparoid or pork products
Active major bleeding or conditions with high risk of hemorrhage
History of immune thrombocytopenia induced by danaparoid
Severe hemorrhagic diathesis such as hemophilia or severe thrombocytopenia

Adverse Reactions

Bleeding and hemorrhage at various sites
Injection site hematoma, pain, or irritation
Thrombocytopenia (cross-reactivity with HIT antibodies is low but possible)
Elevated liver enzymes
Skin rash and allergic reactions

Drug Interactions

Increased bleeding risk with concomitant use of oral anticoagulants (e.g., warfarin)
Increased bleeding risk with antiplatelet agents (e.g., aspirin, NSAIDs, clopidogrel)
Increased risk of hemorrhage with thrombolytic agents
Pharmacodynamic potentiation by other parenteral anticoagulants

Curated Content: Needs Vetting Before Put to Clinical Use